Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunovia AB ( (SE:IMMNOV) ) just unveiled an announcement.
Immunovia AB has secured full guarantee commitments for its upcoming SEK 100 million Rights Issue, ensuring it will be fully subscribed. This financial move is aimed at supporting the company’s efforts to commercialize its PancreaSure test and achieve key milestones, reflecting strong market interest and momentum.
More about Immunovia AB
Immunovia AB operates in the healthcare industry, focusing on the development and commercialization of diagnostic tests. Their primary product, the PancreaSure test, is designed to aid in the early detection of pancreatic cancer. The company is working towards securing insurance reimbursement for this test, which is a significant milestone in their market strategy.
YTD Price Performance: 17.95%
Average Trading Volume: 10,038,451
Technical Sentiment Signal: Hold
Current Market Cap: SEK197.1M
For a thorough assessment of IMMNOV stock, go to TipRanks’ Stock Analysis page.